Initial therapy for mild to moderate clostridium difficile infection

Infectious Diseases in Clinical Practice

Volumn 24, Issue 4, 2016, Pages 210-216

  Siegfried, Justin ^a   Dubrovskaya, Yanina ^a   Flagiello, Thomas ^a   Scipione, Marco R ^a   Phillips, Michael ^a   Papadopoulos, John ^a   Chen, Donald ^a   Safdar, Amar ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

clinical outcomes; Clostridium difficile; mild to moderate disease; NAP1 strain

Indexed keywords

ALBUMIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ADULT; AGE; AGED; CHRONIC LIVER DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; HOSPITAL PATIENT; HUMAN; HYPOALBUMINEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84955594751     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0000000000000375     Document Type: Conference Paper

References (22)

1. Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-Associated Clostridium difficile infection and of healthcare-Associated infection due to methicillin-resistant staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011; 32(4): 387-390
2. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-Associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012; 55(2): 216-223
3. Dubberke ER, OlsenMA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012; 55(suppl 2): S88-S92
4. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-Associated diarrhea in a region of Québec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171(5): 466-472
5. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl JMed. 2008; 359(18): 1932-1940
6. Miller M, Gravel D, Mulvey M, et al. Health care-Associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010; 50(2): 194-201
7. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012; 55(3): 351-357
8. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5): 431-455
9. Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014; 20(suppl 2): 1-26
10. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4): 478-498 quiz 99
11. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45(3): 302-307
12. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-Associated disease. Infect Control Hosp Epidemiol. 2007; 28(2): 140-145
13. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014; 59(3): 345-354
14. Belmares J, Gerding DN, Parada JP, et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007; 55(6): 495-501
15. MillerMA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013; 13: 148
16. AlonsoCD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012; 54(8): 1053-1063
17. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012; 55(12): 1661-1668
18. Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers, andmortality in Clostridiumdifficile infection. Clin Infect Dis. 2013; 56(11): 1589-1600
19. See I, Mu Y, Cohen J, et al. Nap1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014; 58(10): 1394-1400
20. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986; 27(10): 1169-1172
21. Fujitani S, George WL, Morgan MA, et al. Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections. Am J Infect Control. 2011; 39(3): 188-193
22. Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-Associated disease. Antimicrob Agents Chemother. 2008; 52(7): 2403-2406